Stock Events

Novo Nordisk 

$138.31
5172
-$4.67-3.27% Wednesday 19:54

Statistics

Day High
141.52
Day Low
136.01
52W High
148.15
52W Low
74.66
Volume
7,179,327
Avg. Volume
3,745,017
Mkt Cap
471.55B
P/E Ratio
0
Dividend Yield
1.34%
Dividend
1.86

Upcoming

22
SEP
Dividend Ex
3
OCT
Dividend Payment
22
MAR 25
Dividend Ex
2
APR 25
Dividend Payment
22
SEP 25
Dividend Ex
3
OCT 25
Dividend Payment
22
MAR 26
Dividend Ex
2
APR 26
Dividend Payment

Dividends

1.34%Dividend Yield
Apr 24
$0.93
Aug 23
$0.44
Apr 23
$0.59
Aug 22
$0.29
Apr 22
$0.51
10Y Growth
16.17%
5Y Growth
24.83%
3Y Growth
36.17%
1Y Growth
80.72%

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
2.93
5.85
8.78
Expected EPS
N/A
Actual EPS
5.68

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVO. It's not an investment recommendation.
Alphabet
67793
GOOGL
Apple
60008
AAPL
Microsoft
55724
MSFT
Amazon
51409
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap122.89B
Sanofi competes directly with Novo Nordisk in the diabetes and insulin markets, offering similar products and therapies.
Lilly(Eli) &
LLY
Mkt Cap860.48B
Eli Lilly is a major competitor in the diabetes care market, particularly in insulin and GLP-1 receptor agonists, directly competing with Novo Nordisk's portfolio.
Astrazeneca
AZN
Mkt Cap241.81B
AstraZeneca competes in the diabetes sector with its range of type 2 diabetes medications, posing competition to Novo Nordisk's diabetes care products.
Merck &
MRK
Mkt Cap313.56B
Merck is a competitor in the diabetes market with its drug Januvia among others, competing with Novo Nordisk's diabetes management products.
Bristol-Myers Squibb
BMY
Mkt Cap84.19B
Bristol Myers Squibb competes in the area of diabetes and cardiovascular diseases, areas where Novo Nordisk also has a significant presence.
Pfizer
PFE
Mkt Cap158.55B
Pfizer competes with Novo Nordisk in various therapeutic areas, including chronic diseases, though not as directly in diabetes.
Novartis
NVS
Mkt Cap233.14B
Novartis competes across a broad range of therapeutic areas including cardiovascular, which overlaps with Novo Nordisk's interests.
Johnson & Johnson
JNJ
Mkt Cap351.76B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in several areas including diabetes care.
Abbott Laboratories
ABT
Mkt Cap180.77B
Abbott Laboratories competes with Novo Nordisk in the broader healthcare market, including diabetes management through its glucose monitoring devices.
Thermo Fisher Scientific
TMO
Mkt Cap211.09B
Thermo Fisher Scientific competes indirectly by providing instruments and reagents for diabetes research, affecting the market landscape.

Analyst Ratings

150.75$Average Price Target
The highest estimate is $163.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Lars Fruergaard Joergensen
Employees
66015
Country
US
ISIN
US6701002056
WKN
000866931

Listings

VI
AT
NNO2.VI
LSE
GB
0TDD.LSE
OTCM
US
NONOF
XNYS
US
NVO